Format

Send to

Choose Destination
Obes Res Clin Pract. 2018 Jul 20;12(5):465-471. doi: 10.1016/j.orcp.2018.07.007.

Multicentre, placebo-controlled trial of lorcaserin for weight management in Chinese population.

Author information

1
Department of Family Medicine, National Taiwan University Hospital, Taipei, Taiwan; Department of Family Medicine, College of Medicine, National Taiwan University, Taipei, Taiwan; Institute of Population Health Sciences, National Health Research Institutes, Zhunan, Miaoli County, Taiwan.
2
Department of Family Medicine, National Cheng Kung University Hospital, Tainan, Taiwan; Department of Family Medicine, College of Medicine, National Cheng Kung University, Taichung, Taiwan.
3
Department of Family Medicine, National Cheng Kung University Hospital, Tainan, Taiwan; Department of Family Medicine, College of Medicine, National Cheng Kung University, Taichung, Taiwan; Tainan Hospital, Ministry of Health and Welfare, Tainan, Taiwan.
4
Department of Family Medicine, China Medical University Hospital, Taichung, Taiwan; Department of Family Medicine and Social Medicine, School of Medicine, China Medical University, Taichung, Taiwan. Electronic address: wylin@mail.cmu.edu.tw.
5
Department of Family Medicine, National Taiwan University Hospital, Taipei, Taiwan; Department of Family Medicine, College of Medicine, National Taiwan University, Taipei, Taiwan; Institute of Population Health Sciences, National Health Research Institutes, Zhunan, Miaoli County, Taiwan; Department of Family Medicine, National Taiwan University Hospital Bei-Hu Branch, Taipei, Taiwan. Electronic address: bretthuang@ntu.edu.tw.

Abstract

OBJECTIVE:

This study aimed to evaluate the effects of lorcaserin on body weight, cardiovascular risk factors, and safety in obese patients in Taiwan.

METHODS:

In this double-blind, randomised controlled trial, 171 obese adults were assigned to receive lorcaserin at a dose of 10mg, or placebo, twice a day for 24weeks. Diet and exercise counselling were given to all patients through the treatment period. Primary outcomes were proportion of patients achieving at least 5% and 10% reduction in body weight and mean change in body weight. Safety and tolerability endpoints such as Beck Depression Inventory-II, blood biochemistry, vital signs, and electrocardiogram were monitored.

RESULTS:

More patients receiving lorcaserin lost at least 5% body weight than receiving placebo (52.4% and 28.1%, P=0.001) with an average weight reduction of 5.8kg (95% CI: -6.91, -4.70) in lorcaserin group and those of 3.6kg (95% CI: -4.95, -2.33) in placebo group (P<0.05). The most common adverse effect with greater incidence in the lorcaserin group was self-limited dizziness. Serious adverse effect were rare and was reported by slightly more patients taking placebo than lorcaserin.

CONCLUSIONS:

In this multicentre, double-blinded placebo-controlled trial, lorcaserin was effective and well-tolerable in Asia group.

KEYWORDS:

5-HT; Anti-obese drug; Lorcaserin; Obesity; Weight reduction

PMID:
30033356
DOI:
10.1016/j.orcp.2018.07.007
[Indexed for MEDLINE]

Supplemental Content

Loading ...
Support Center